Australian biotech market watch 05/03/10
Friday, 05 March, 2010
Not even an interest rate rise could put a dampener on the stock market this week, with the All Ordinaries up by 125 points, or 2.7 per cent, from Monday.
In contrast, the life sciences index has been a little more turbulent, slipping through to Thursday before a rebound in trading this morning to 8,733.
The lion's share of the rebound is due to the biotech gorilla, CSL (ASX:CSL), bumping up 66c, or 1.9 per cent, to $35.45, following news that CSL's subsidiary, CSL Behring, has been given the go ahead by the US Food and Drug Administration to market a new blood plasma product.
ResMed (ASX:RMD) also saw an 8c lift to $6.60.
The rest of the market has been relatively steady, although Primary Health Care did take an 11c dip to $4.15.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
